Cargando…

The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice

BACKGROUND: Liver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the scavenger receptor class B type I (SR-BI). Here, we investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tancevski, Ivan, Demetz, Egon, Eller, Philipp, Duwensee, Kristina, Hoefer, Julia, Heim, Christiane, Stanzl, Ursula, Wehinger, Andreas, Auer, Kristina, Karer, Regina, Huber, Julia, Schgoer, Wilfried, Van Eck, Miranda, Vanhoutte, Jonathan, Fievet, Catherine, Stellaard, Frans, Rudling, Mats, Patsch, Josef R., Ritsch, Andreas
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806908/
https://www.ncbi.nlm.nih.gov/pubmed/20090943
http://dx.doi.org/10.1371/journal.pone.0008722
_version_ 1782176348474703872
author Tancevski, Ivan
Demetz, Egon
Eller, Philipp
Duwensee, Kristina
Hoefer, Julia
Heim, Christiane
Stanzl, Ursula
Wehinger, Andreas
Auer, Kristina
Karer, Regina
Huber, Julia
Schgoer, Wilfried
Van Eck, Miranda
Vanhoutte, Jonathan
Fievet, Catherine
Stellaard, Frans
Rudling, Mats
Patsch, Josef R.
Ritsch, Andreas
author_facet Tancevski, Ivan
Demetz, Egon
Eller, Philipp
Duwensee, Kristina
Hoefer, Julia
Heim, Christiane
Stanzl, Ursula
Wehinger, Andreas
Auer, Kristina
Karer, Regina
Huber, Julia
Schgoer, Wilfried
Van Eck, Miranda
Vanhoutte, Jonathan
Fievet, Catherine
Stellaard, Frans
Rudling, Mats
Patsch, Josef R.
Ritsch, Andreas
author_sort Tancevski, Ivan
collection PubMed
description BACKGROUND: Liver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the scavenger receptor class B type I (SR-BI). Here, we investigated the effect of the thyromimetic T-0681 on reverse cholesterol transport (RCT) and atherosclerosis, and studied the underlying mechanisms using different mouse models, including mice lacking LDLr, SR-BI, and apoE, as well as CETP transgenic mice. METHODOLOGY/PRINCIPAL FINDINGS: T-0681 treatment promoted bile acid production and biliary sterol secretion consistently in the majority of the studied mouse models, which was associated with a marked reduction of plasma cholesterol. Using an assay of macrophage RCT in mice, we found T-0681 to significantly increase fecal excretion of macrophage-derived neutral and acidic sterols. No positive effect on RCT was found in CETP transgenic mice, most likely due to the observed decrease in plasma CETP mass. Studies in SR-BI KO and LDLr KO mice suggested hepatic LDLr to be necessary for the action of T-0681 on lipid metabolism, as the compound did not have any influence on plasma cholesterol levels in mice lacking this receptor. Finally, prolonged treatment with T-0681 reduced the development of atherosclerosis by 60% in apoE KOs on Western type diet. In contrast, at an earlier time-point T-0681 slightly increased small fatty streak lesions, in part due to an impaired macrophage cholesterol efflux capacity, when compared to controls. CONCLUSIONS/SIGNIFICANCE: The present results show that liver-selective thyromimetics can promote RCT and that such compounds may protect from atherosclerosis partly through induction of bile acid metabolism and biliary sterol secretion. On-going clinical trials will show whether selective thyromimetics do prevent atherosclerosis also in humans.
format Text
id pubmed-2806908
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28069082010-01-21 The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice Tancevski, Ivan Demetz, Egon Eller, Philipp Duwensee, Kristina Hoefer, Julia Heim, Christiane Stanzl, Ursula Wehinger, Andreas Auer, Kristina Karer, Regina Huber, Julia Schgoer, Wilfried Van Eck, Miranda Vanhoutte, Jonathan Fievet, Catherine Stellaard, Frans Rudling, Mats Patsch, Josef R. Ritsch, Andreas PLoS One Research Article BACKGROUND: Liver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the scavenger receptor class B type I (SR-BI). Here, we investigated the effect of the thyromimetic T-0681 on reverse cholesterol transport (RCT) and atherosclerosis, and studied the underlying mechanisms using different mouse models, including mice lacking LDLr, SR-BI, and apoE, as well as CETP transgenic mice. METHODOLOGY/PRINCIPAL FINDINGS: T-0681 treatment promoted bile acid production and biliary sterol secretion consistently in the majority of the studied mouse models, which was associated with a marked reduction of plasma cholesterol. Using an assay of macrophage RCT in mice, we found T-0681 to significantly increase fecal excretion of macrophage-derived neutral and acidic sterols. No positive effect on RCT was found in CETP transgenic mice, most likely due to the observed decrease in plasma CETP mass. Studies in SR-BI KO and LDLr KO mice suggested hepatic LDLr to be necessary for the action of T-0681 on lipid metabolism, as the compound did not have any influence on plasma cholesterol levels in mice lacking this receptor. Finally, prolonged treatment with T-0681 reduced the development of atherosclerosis by 60% in apoE KOs on Western type diet. In contrast, at an earlier time-point T-0681 slightly increased small fatty streak lesions, in part due to an impaired macrophage cholesterol efflux capacity, when compared to controls. CONCLUSIONS/SIGNIFICANCE: The present results show that liver-selective thyromimetics can promote RCT and that such compounds may protect from atherosclerosis partly through induction of bile acid metabolism and biliary sterol secretion. On-going clinical trials will show whether selective thyromimetics do prevent atherosclerosis also in humans. Public Library of Science 2010-01-15 /pmc/articles/PMC2806908/ /pubmed/20090943 http://dx.doi.org/10.1371/journal.pone.0008722 Text en Tancevski et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tancevski, Ivan
Demetz, Egon
Eller, Philipp
Duwensee, Kristina
Hoefer, Julia
Heim, Christiane
Stanzl, Ursula
Wehinger, Andreas
Auer, Kristina
Karer, Regina
Huber, Julia
Schgoer, Wilfried
Van Eck, Miranda
Vanhoutte, Jonathan
Fievet, Catherine
Stellaard, Frans
Rudling, Mats
Patsch, Josef R.
Ritsch, Andreas
The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title_full The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title_fullStr The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title_full_unstemmed The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title_short The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice
title_sort liver-selective thyromimetic t-0681 influences reverse cholesterol transport and atherosclerosis development in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806908/
https://www.ncbi.nlm.nih.gov/pubmed/20090943
http://dx.doi.org/10.1371/journal.pone.0008722
work_keys_str_mv AT tancevskiivan theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT demetzegon theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT ellerphilipp theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT duwenseekristina theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT hoeferjulia theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT heimchristiane theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT stanzlursula theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT wehingerandreas theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT auerkristina theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT karerregina theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT huberjulia theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT schgoerwilfried theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT vaneckmiranda theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT vanhouttejonathan theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT fievetcatherine theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT stellaardfrans theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT rudlingmats theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT patschjosefr theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT ritschandreas theliverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT tancevskiivan liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT demetzegon liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT ellerphilipp liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT duwenseekristina liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT hoeferjulia liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT heimchristiane liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT stanzlursula liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT wehingerandreas liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT auerkristina liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT karerregina liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT huberjulia liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT schgoerwilfried liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT vaneckmiranda liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT vanhouttejonathan liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT fievetcatherine liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT stellaardfrans liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT rudlingmats liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT patschjosefr liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice
AT ritschandreas liverselectivethyromimetict0681influencesreversecholesteroltransportandatherosclerosisdevelopmentinmice